17 completed, 5 terminated, 4 recruiting. 15 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 9, Recruiting 3, Terminated 3 |
| Phase 2 | 11 | Completed 8, Terminated 2, Recruiting 1 |
Follow Best Supportive Care (BSC): new trials by email Literature Review of Best Supportive Care (BSC) trials Research Report on Best Supportive Care (BSC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Samsung Medical Center | 48 | 2025-09-16 | 2025-11-06 |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) Pasritamig, Placebo, Best Supportive Care (BSC) - Metastatic Castration-resistant Prostatic Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1203 | 2025-09-02 | 2026-09-25 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma Cabozantinib, Best Supportive Care (BSC) - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Terminated | Ipsen | 10 | 2024-11-22 | 2026-03-31 |
| Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis Cellgram-LC, Best Supportive Care (BSC) - Alcoholic Cirrhosis | Phase 3 | Recruiting | Pharmicell Co., Ltd. | 200 | 2021-04-19 | 2026-09-21 |
| Efficacy and Safety of Itolizumab in COVID-19 Complications Itolizumab IV infusion, Best supportive care (BSC) - Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 2 | Completed | Biocon Limited | 32 | 2020-05-01 | 2021-06-14 |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) Venetoclax, Azacitidine, Best Supportive Care (BSC) - Acute Myeloid Leukemia (AML), Cancer | Phase 3 | Terminated | AbbVie | 465 | 2020-02-26 | 2026-06-04 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia Luspatercept, Placebo, Best Supportive Care (BSC) - Thalassemia | Phase 2 | Completed | Celgene | 145 | 2018-02-05 | 2023-12-20 |
| Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) pembrolizumab, placebo, best supportive care (BSC) - Carcinoma, Hepatocellular | Phase 3 | Completed | Merck Sharp & Dohme LLC | 453 | 2017-04-27 | 2025-09-30 |
| Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Avelumab, Irinotecan, Paclitaxel - Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 371 | 2015-12-28 | 2020-11-24 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS | Phase 3 | Terminated | Traws Pharma, Inc. | 372 | 2015-12-02 | 2022-09-26 |
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma capecitabine, Best supportive care (BSC) - Nasopharyngeal Carcinoma | Phase 3 | Completed | Sun Yat-sen University | 104 | 2015-04-01 | 2022-10-28 |
| Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC) - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 185 | 2014-10-13 | 2025-08-07 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC) - Metastatic Colorectal Cancer | Phase 2 | Completed | Symphogen A/S | 254 | 2014-03-06 | 2019-04-16 |
| An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy Ipilimumab, Best Supportive care (BSC) - Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction | Phase 2 | Completed | Bristol-Myers Squibb | 143 | 2012-07-01 | 2016-05-17 |
| A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia Azacitidine, Lenalidomide, Best Supportive Care (BSC) - Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 2 | Completed | Celgene | 88 | 2012-04-27 | 2019-06-25 |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome Siltuximab, Placebo, Best supportive care (BSC) - Myelodysplastic Syndrome | Phase 2 | Terminated | Janssen Research & Development, LLC | 76 | 2011-11-01 | 2014-09-29 |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer Best Supportive Care (BSC), Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Amgen | 377 | 2011-11-01 | 2017-03-15 |
| Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy Regorafenib (Stivarga, BAY73-4506), Placebo, Best Supportive Care (BSC) - Metastatic Colorectal Cancer | Phase 3 | Completed | Bayer | 760 | 2010-04-01 | 2015-06-24 |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. Everolimus, Everolimus Placebo, Best Supportive Care (BSC) - Carcinoma | Phase 3 | Completed | Novartis Pharmaceuticals | 546 | 2010-04-01 | 2016-09-22 |
Showing 20 of 26. Sign in to see all of them.
Colorectal Neoplasms (3) · Myelodysplastic Syndromes (3) · Stomach Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Adenocarcinoma (1) · Anemia, Refractory, with Excess of Blasts (1) · Biliary Tract Neoplasms (1) · COVID-19 (1) · Carcinoma (1) · Cholangiocarcinoma (1)
Janssen Research & Development, LLC (3) · Celgene (2) · Merck KGaA, Darmstadt, Germany (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Amgen (1) · Bayer (1) · Biocon Limited (1) · Bristol-Myers Squibb (1) · EMD Serono Research & Development Institute, Inc. (1) · Eli Lilly and Company (1) · Ipsen (1) · J-Pharma Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1)
United States (17) · South Korea (13) · Spain (13) · Germany (12) · Italy (12) · Canada (11) · China (11) · France (11) · Australia (10) · Belgium (10) · Taiwan (9) · United Kingdom (8) · Japan (7) · Poland (7) · Russia (7)
Eric K Rowinsky, MD (1) · Ghassan Abou-Alfa, MD (1) · Guillermo Garcia-Manero (1) · Jeevan Shetty, MD (1) · Josep Tabernero, MD, PhD (1)
PMID 16170175, PMID 21744082, PMID 21982342, PMID 22421192, PMID 23177514, PMID 24043745, PMID 24094768, PMID 25042199, PMID 25058218, PMID 26184520, PMID 27130844, PMID 28087540, PMID 28716815, PMID 29097499, PMID 30052729, PMID 30557792, PMID 33708965, PMID 34870327, PMID 35175316, PMID 35623069, PMID 35793409, PMID 36007538, PMID 36777769, PMID 36948565, PMID 37704579, PMID 38861286, PMID 40486134, PMID 40875596, PMID 41857682
2009 (3), 2015 (3), 2008 (2), 2023 (2), 2025 (1)